TY - JOUR PY - 2016 DA - 2016// TI - Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 JO - Lancet VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)31678-6 DO - 10.1016/S0140-6736(16)31678-6 ID - ref1 ER - TY - JOUR AU - Stovner, L. J. AU - Andree, C. PY - 2010 DA - 2010// TI - Prevalence of headache in Europe: a review for the Eurolight project JO - J Headache Pain VL - 11 UR - https://doi.org/10.1007/s10194-010-0217-0 DO - 10.1007/s10194-010-0217-0 ID - Stovner2010 ER - TY - JOUR AU - Victor, T. AU - Hu, X. AU - Campbell, J. AU - Buse, D. AU - Lipton, R. PY - 2010 DA - 2010// TI - Migraine prevalence by age and sex in the United States: a life-span study JO - Cephalalgia VL - 30 UR - https://doi.org/10.1177/0333102409355601 DO - 10.1177/0333102409355601 ID - Victor2010 ER - TY - JOUR AU - Bigal, M. E. AU - Serrano, D. AU - Reed, M. AU - Lipton, R. B. PY - 2008 DA - 2008// TI - Chronic migraine in the population - burden, diagnosis, and satisfaction with treatment JO - Neurology VL - 71 UR - https://doi.org/10.1212/01.wnl.0000323925.29520.e7 DO - 10.1212/01.wnl.0000323925.29520.e7 ID - Bigal2008 ER - TY - JOUR AU - Friedman, A. P. AU - Losin, S. PY - 1961 DA - 1961// TI - Evaluation of UML-491 in the treatment of vascular headaches. An analysis of the effects of 1-methyl-D-lysergic acid (plus) butanolamide bimaleate (methysergide) JO - Arch Neurol VL - 4 UR - https://doi.org/10.1001/archneur.1961.00450090007002 DO - 10.1001/archneur.1961.00450090007002 ID - Friedman1961 ER - TY - JOUR AU - Aurora, S. K. AU - Dodick, D. W. AU - Turkel, C. C. AU - DeGryse, R. E. AU - Silberstein, S. D. AU - Lipton, R. B. AU - Diener, H. C. AU - Brin, M. F. PY - 2010 DA - 2010// TI - OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial JO - Cephalalgia VL - 30 UR - https://doi.org/10.1177/0333102410364676 DO - 10.1177/0333102410364676 ID - Aurora2010 ER - TY - JOUR AU - Diener, H. C. AU - Dodick, D. W. AU - Aurora, S. K. AU - Turkel, C. C. AU - DeGryse, R. E. AU - Lipton, R. B. AU - Silberstein, S. D. AU - Brin, M. F. PY - 2010 DA - 2010// TI - PREEMPT 2 chronic migraine study group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial JO - Cephalalgia VL - 30 UR - https://doi.org/10.1177/0333102410364677 DO - 10.1177/0333102410364677 ID - Diener2010 ER - TY - JOUR AU - Silberstein, S. D. AU - Neto, W. AU - Schmitt, J. AU - Jacobs, D. PY - 2004 DA - 2004// TI - Topiramate in migraine prevention: results of a large controlled trial JO - Arch Neurol VL - 61 UR - https://doi.org/10.1001/archneur.61.4.490 DO - 10.1001/archneur.61.4.490 ID - Silberstein2004 ER - TY - JOUR AU - Silberstein, S. D. AU - Holland, S. AU - Freitag, F. AU - Dodick, D. W. AU - Argoff, C. AU - Ashman, E. PY - 2012 DA - 2012// TI - Quality standards Subcommittee of the American Academy of neurology and the American headache society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards Subcommittee of the American Academy of neurology and the American headache society JO - Neurology VL - 78 UR - https://doi.org/10.1212/WNL.0b013e3182535d20 DO - 10.1212/WNL.0b013e3182535d20 ID - Silberstein2012 ER - TY - JOUR AU - Luykx, J. AU - Mason, M. AU - Ferrari, M. D. AU - Carpay, J. PY - 2009 DA - 2009// TI - Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine JO - Clin Pharmacol Ther VL - 85 UR - https://doi.org/10.1038/clpt.2008.203 DO - 10.1038/clpt.2008.203 ID - Luykx2009 ER - TY - JOUR AU - Berger, A. AU - Bloudek, L. M. AU - Varon, S. F. AU - Oster, G. PY - 2012 DA - 2012// TI - Adherence with migraine prophylaxis in clinical practice JO - Pain Pract VL - 12 UR - https://doi.org/10.1111/j.1533-2500.2012.00530.x DO - 10.1111/j.1533-2500.2012.00530.x ID - Berger2012 ER - TY - JOUR AU - Diamond, S. AU - Bigal, M. E. AU - Silberstein, S. AU - Loder, E. AU - Reed, M. AU - Lipton, R. B. PY - 2007 DA - 2007// TI - Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American migraine prevalence and prevention study JO - Headache VL - 47 ID - Diamond2007 ER - TY - JOUR AU - Loder, E. W. AU - Rizzoli, P. PY - 2011 DA - 2011// TI - Tolerance and loss of beneficial effect during migraine prophylaxis: clinical considerations JO - Headache VL - 51 UR - https://doi.org/10.1111/j.1526-4610.2011.01986.x DO - 10.1111/j.1526-4610.2011.01986.x ID - Loder2011 ER - TY - JOUR AU - Hepp, Z. AU - Dodick, D. W. AU - Varon, S. F. AU - Gillard, P. AU - Hansen, R. N. AU - Devine, E. B. PY - 2015 DA - 2015// TI - Adherence to oral migraine-preventive medications among patients with chronic migraine JO - Cephalalgia VL - 35 UR - https://doi.org/10.1177/0333102414547138 DO - 10.1177/0333102414547138 ID - Hepp2015 ER - TY - JOUR AU - Martelletti, P. PY - 2017 DA - 2017// TI - The application of CGRP(r) monoclonal antibodies in migraine spectrum: needs and priorities JO - BioDrugs VL - 31 UR - https://doi.org/10.1007/s40259-017-0251-4 DO - 10.1007/s40259-017-0251-4 ID - Martelletti2017 ER - TY - JOUR AU - Mitsikostas, D. D. AU - Reuter, U. PY - 2017 DA - 2017// TI - Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies JO - Curr Opin Neurol VL - 30 UR - https://doi.org/10.1097/WCO.0000000000000438 DO - 10.1097/WCO.0000000000000438 ID - Mitsikostas2017 ER - TY - JOUR AU - Reuter, U. PY - 2018 DA - 2018// TI - A review of monoclonal antibody therapies and other preventative treatments in migraine JO - Headache VL - 58 Suppl 1 UR - https://doi.org/10.1111/head.13302 DO - 10.1111/head.13302 ID - Reuter2018 ER - TY - STD TI - The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system http://gdt.guidelinedevelopment.org/app/handbook/handbook.html (Accessed, 12 June 2018) UR - http://gdt.guidelinedevelopment.org/app/handbook/handbook.html ID - ref18 ER - TY - JOUR AU - Moher, D. AU - Liberati, A. AU - Tetzlaff, J. AU - Altman, D. G. PY - 2009 DA - 2009// TI - Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement JO - PLoS Med VL - 6 ID - Moher2009 ER - TY - JOUR AU - Guyatt, G. H. AU - Oxman, A. D. AU - Vist, G. AU - Kunz, R. AU - Brozek, J. AU - Alonso-Coello, P. AU - Montori, V. AU - Akl, E. A. AU - Djulbegovic, B. AU - Falck-Ytter, Y. AU - Norris, S. L. AU - Williams, J. W. AU - Atkins, D. AU - Meerpohl, J. AU - Schünemann, H. J. PY - 2011 DA - 2011// TI - GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias) JO - J Clin Epidemiol VL - 64 UR - https://doi.org/10.1016/j.jclinepi.2010.07.017 DO - 10.1016/j.jclinepi.2010.07.017 ID - Guyatt2011 ER - TY - JOUR AU - Guyatt, G. H. AU - Oxman, A. D. AU - Sultan, S. AU - Glasziou, P. AU - Akl, E. A. AU - Alonso-Coello, P. AU - Atkins, D. AU - Kunz, R. AU - Brozek, J. AU - Montori, V. AU - Jaeschke, R. AU - Rind, D. AU - Dahm, P. AU - Meerpohl, J. AU - Vist, G. AU - Berliner, E. AU - Norris, S. AU - Falck-Ytter, Y. AU - Murad, M. H. AU - Schünemann, H. J. PY - 2011 DA - 2011// TI - GRADE working group. GRADE guidelines: 9. Rating up the quality of evidence JO - J Clin Epidemiol VL - 64 UR - https://doi.org/10.1016/j.jclinepi.2011.06.004 DO - 10.1016/j.jclinepi.2011.06.004 ID - Guyatt2011 ER - TY - BOOK AU - Dalkey, N. C. AU - Helmer-Hirschberg, O. PY - 1962 DA - 1962// TI - An experimental application of the delphi method to the use of experts PB - Rand Corp CY - Santa Monica ID - Dalkey1962 ER - TY - JOUR AU - Ayer, D. W. AU - Skljarevski, V. AU - Ford, J. H. AU - Nyhuis, A. W. AU - Lipton, R. B. AU - Aurora, S. K. PY - 2018 DA - 2018// TI - Measures of functioning in patients with episodic migraine: findings from a double-blind, randomized, placebo-controlled phase 2b trial with galcanezumab JO - Headache VL - 58 UR - https://doi.org/10.1111/head.13383 DO - 10.1111/head.13383 ID - Ayer2018 ER - TY - JOUR AU - Ashina, M. AU - Dodick, D. AU - Goadsby, P. J. AU - Reuter, U. AU - Silberstein, S. AU - Zhang, F. AU - Gage, J. R. AU - Cheng, S. AU - Mikol, D. D. AU - Lenz, R. A. PY - 2017 DA - 2017// TI - Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study JO - Neurology VL - 89 UR - https://doi.org/10.1212/WNL.0000000000004391 DO - 10.1212/WNL.0000000000004391 ID - Ashina2017 ER - TY - JOUR AU - Ashina, M. AU - Tepper, S. AU - Brandes, J. L. AU - Reuter, U. AU - Boudreau, G. AU - Dolezil, D. AU - Cheng, S. AU - Zhang, F. AU - Lenz, R. AU - Klatt, J. AU - Mikol, D. D. PY - 2018 DA - 2018// TI - Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study JO - Cephalalgia VL - 38 UR - https://doi.org/10.1177/0333102418788347 DO - 10.1177/0333102418788347 ID - Ashina2018 ER - TY - JOUR AU - Bigal, M. E. AU - Edvinsson, L. AU - Rapoport, A. M. AU - Lipton, R. B. AU - Spierings, E. L. AU - Diener, H. C. AU - Burstein, R. AU - Loupe, P. S. AU - Ma, Y. AU - Yang, R. PY - 2015 DA - 2015// TI - Silberstein SD (2015a) safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study JO - Lancet Neurol VL - 14 UR - https://doi.org/10.1016/S1474-4422(15)00245-8 DO - 10.1016/S1474-4422(15)00245-8 ID - Bigal2015 ER - TY - JOUR AU - Bigal, M. E. AU - Dodick, D. W. AU - Rapoport, A. M. AU - Silberstein, S. D. AU - Ma, Y. AU - Yang, R. AU - Loupe, P. S. AU - Burstein, R. AU - Newman, L. C. AU - Lipton, R. B. PY - 2015 DA - 2015// TI - Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study JO - Lancet Neurol VL - 14 UR - https://doi.org/10.1016/S1474-4422(15)00249-5 DO - 10.1016/S1474-4422(15)00249-5 ID - Bigal2015 ER - TY - JOUR AU - Bigal, M. E. AU - Dodick, D. W. AU - Krymchantowski, A. V. AU - VanderPluym, J. H. AU - Tepper, S. J. AU - Aycardi, E. AU - Loupe, P. S. AU - Ma, Y. AU - Goadsby, P. J. PY - 2016 DA - 2016// TI - TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points JO - Neurology VL - 87 UR - https://doi.org/10.1212/WNL.0000000000002801 DO - 10.1212/WNL.0000000000002801 ID - Bigal2016 ER - TY - JOUR AU - Buse, D. C. AU - Lipton, R. B. AU - Hallström, Y. AU - Reuter, U. AU - Tepper, S. J. AU - Zhang, F. AU - Sapra, S. AU - Picard, H. AU - Mikol, D. D. AU - Lenz, R. A. PY - 2018 DA - 2018// TI - Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab JO - Cephalalgia VL - 38 UR - https://doi.org/10.1177/0333102418789072 DO - 10.1177/0333102418789072 ID - Buse2018 ER - TY - JOUR AU - Cohen, J. M. AU - Dodick, D. W. AU - Yang, R. AU - Newman, L. C. AU - Li, T. AU - Aycardi, E. AU - Bigal, M. E. PY - 2017 DA - 2017// TI - Fremanezumab as add-on treatment for patients treated with other migraine preventive medicines JO - Headache VL - 57 UR - https://doi.org/10.1111/head.13156 DO - 10.1111/head.13156 ID - Cohen2017 ER - TY - JOUR AU - Detke, H. C. AU - Goadsby, P. J. AU - Wang, S. AU - Friedman, D. I. AU - Selzler, K. J. AU - Aurora, S. K. PY - 2018 DA - 2018// TI - Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study JO - Neurology VL - 91 UR - https://doi.org/10.1212/WNL.0000000000006640. DO - 10.1212/WNL.0000000000006640. ID - Detke2018 ER - TY - JOUR AU - Dodick, D. W. AU - Goadsby, P. J. AU - Silberstein, S. D. AU - Lipton, R. B. AU - Olesen, J. AU - Ashina, M. AU - Wilks, K. AU - Kudrow, D. AU - Kroll, R. AU - Kohrman, B. AU - Bargar, R. AU - Hirman, J. AU - Smith, J. PY - 2014 DA - 2014// TI - ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial JO - Lancet Neurol VL - 13 UR - https://doi.org/10.1016/S1474-4422(14)70209-1 DO - 10.1016/S1474-4422(14)70209-1 ID - Dodick2014 ER - TY - JOUR AU - Dodick, D. W. AU - Goadsby, P. J. AU - Spierings, E. L. AU - Scherer, J. C. AU - Sweeney, S. P. PY - 2014 DA - 2014// TI - Grayzel. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study JO - Lancet Neurol VL - 13 UR - https://doi.org/10.1016/S1474-4422(14)70128-0 DO - 10.1016/S1474-4422(14)70128-0 ID - Dodick2014 ER - TY - JOUR AU - Dodick, D. W. AU - Silberstein, S. D. AU - Bigal, M. E. AU - Yeung, P. P. AU - Goadsby, P. J. AU - Blankenbiller, T. AU - Grozinski-Wolff, M. AU - Yang, R. AU - Ma, Y. AU - Aycardi, E. PY - 2018 DA - 2018// TI - Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial JO - JAMA VL - 319 UR - https://doi.org/10.1001/jama.2018.4853 DO - 10.1001/jama.2018.4853 ID - Dodick2018 ER - TY - JOUR AU - Dodick, D. W. AU - Ashina, M. AU - Brandes, J. L. AU - Kudrow, D. AU - Lanteri-Minet, M. AU - Osipova, V. AU - Palmer, K. AU - Picard, H. AU - Mikol, D. D. AU - Lenz, R. A. PY - 2018 DA - 2018// TI - ARISE: a phase 3 randomized trial of erenumab for episodic migraine JO - Cephalalgia VL - 38 UR - https://doi.org/10.1177/0333102418759786 DO - 10.1177/0333102418759786 ID - Dodick2018 ER - TY - JOUR AU - Goadsby, P. J. AU - Reuter, U. AU - Hallström, Y. AU - Broessner, G. AU - Bonner, J. H. AU - Zhang, F. AU - Sapra, S. AU - Picard, H. AU - Mikol, D. D. AU - Lenz, R. A. PY - 2017 DA - 2017// TI - A controlled trial of erenumab for episodic migraine JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1705848 DO - 10.1056/NEJMoa1705848 ID - Goadsby2017 ER - TY - STD TI - Halker Singh RB, Aycardi E, Bigal ME, Loupe PS, McDonald M, Dodick DW (2018) Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: post-hoc analyses from phase 2 trials. Cephalalgia. https://doi.org/10.1177/0333102418772585 ID - ref37 ER - TY - JOUR AU - Oakes, T. M. M. AU - Skljarevski, V. AU - Zhang, Q. AU - Kielbasa, W. AU - Hodsdon, M. E. AU - Detke, H. C. AU - Camporeale, A. AU - Saper, J. R. PY - 2018 DA - 2018// TI - Safety of galcanezumab in patients with episodic migraine: a randomized placebo-controlled dose-ranging phase 2b study JO - Cephalalgia VL - 38 UR - https://doi.org/10.1177/0333102417747230 DO - 10.1177/0333102417747230 ID - Oakes2018 ER - TY - JOUR AU - Rosen, N. AU - Pearlman, E. AU - Ruff, D. AU - Day, K. AU - Jim Nagy, A. PY - 2018 DA - 2018// TI - 100% response rate to galcanezumab in patients with episodic migraine: a post hoc analysis of the results from phase 3, randomized, double-blind, placebo-controlled EVOLVE-1 and EVOLVE-2 studies JO - Headache VL - 58 UR - https://doi.org/10.1111/head.13427 DO - 10.1111/head.13427 ID - Rosen2018 ER - TY - JOUR AU - Schwedt, T. AU - Reuter, U. AU - Tepper, S. AU - Ashina, M. AU - Kudrow, D. AU - Broessner, G. AU - Boudreau, G. P. AU - McAllister, P. AU - Vu, T. AU - Zhang, F. AU - Cheng, S. AU - Picard, H. AU - Wen, S. AU - Kahn, J. AU - Klatt, J. AU - Mikol, D. PY - 2018 DA - 2018// TI - Early onset of efficacy with erenumab in patients with episodic and chronic migraine JO - J Headache Pain VL - 19 UR - https://doi.org/10.1186/s10194-018-0923-6 DO - 10.1186/s10194-018-0923-6 ID - Schwedt2018 ER - TY - JOUR AU - Silberstein, S. D. AU - Dodick, D. W. AU - Bigal, M. E. AU - Yeung, P. P. AU - Goadsby, P. J. AU - Blankenbiller, T. AU - Grozinski-Wolff, M. AU - Yang, R. AU - Ma, Y. AU - Aycardi, E. PY - 2017 DA - 2017// TI - Fremanezumab for the preventive treatment of chronic migraine JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1709038 DO - 10.1056/NEJMoa1709038 ID - Silberstein2017 ER - TY - JOUR AU - Skljarevski, V. AU - Oakes, T. M. AU - Zhang, Q. AU - Ferguson, M. B. AU - Martinez, J. AU - Camporeale, A. AU - Johnson, K. W. AU - Shan, Q. AU - Carter, J. AU - Schacht, A. AU - Goadsby, P. J. AU - Dodick, D. W. PY - 2018 DA - 2018// TI - Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial JO - JAMA Neurol VL - 75 UR - https://doi.org/10.1001/jamaneurol.2017.3859 DO - 10.1001/jamaneurol.2017.3859 ID - Skljarevski2018 ER - TY - JOUR AU - Stauffer, V. L. AU - Dodick, D. W. AU - Zhang, Q. AU - Carter, J. N. AU - Ailani, J. AU - Conley, R. R. PY - 2018 DA - 2018// TI - Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial JO - JAMA Neurol VL - 75 UR - https://doi.org/10.1001/jamaneurol.2018.1212 DO - 10.1001/jamaneurol.2018.1212 ID - Stauffer2018 ER - TY - JOUR AU - Sun, H. AU - Dodick, D. W. AU - Silberstein, S. AU - Goadsby, P. J. AU - Reuter, U. AU - Ashina, M. AU - Saper, J. AU - Cady, R. AU - Chon, Y. AU - Dietrich, J. AU - Lenz, R. PY - 2016 DA - 2016// TI - Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial JO - Lancet Neurol VL - 15 UR - https://doi.org/10.1016/S1474-4422(16)00019-3 DO - 10.1016/S1474-4422(16)00019-3 ID - Sun2016 ER - TY - JOUR AU - Tepper, S. AU - Ashina, M. AU - Reuter, U. AU - Brandes, J. L. AU - Doležil, D. AU - Silberstein, S. AU - Winner, P. AU - Leonardi, D. AU - Mikol, D. AU - Lenz, R. PY - 2017 DA - 2017// TI - Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial JO - Lancet Neurol VL - 16 UR - https://doi.org/10.1016/S1474-4422(17)30083-2 DO - 10.1016/S1474-4422(17)30083-2 ID - Tepper2017 ER - TY - JOUR AU - VanderPluym, J. AU - Dodick, D. W. AU - Lipton, R. B. AU - Ma, Y. AU - Loupe, P. S. AU - Bigal, M. E. PY - 2018 DA - 2018// TI - Fremanezumab for preventive treatment of migraine: functional status on headache-free days JO - Neurology VL - 91 UR - https://doi.org/10.1212/01.wnl.0000544321.19316.40 DO - 10.1212/01.wnl.0000544321.19316.40 ID - VanderPluym2018 ER - TY - JOUR AU - Camporeale, A. AU - Kudrow, D. AU - Sides, R. AU - Wang, S. AU - Dycke, A. AU - Selzler, K. J. AU - Stauffer, V. L. PY - 2018 DA - 2018// TI - A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine JO - BMC Neurol VL - 18 UR - https://doi.org/10.1186/s12883-018-1193-2 DO - 10.1186/s12883-018-1193-2 ID - Camporeale2018 ER - TY - JOUR AU - Ford, J. H. AU - Foster, S. A. AU - Stauffer, V. L. AU - Ruff, D. D. AU - Aurora, S. K. AU - Versijpt, J. PY - 2018 DA - 2018// TI - Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine JO - Patient Prefer Adherence VL - 12 UR - https://doi.org/10.2147/PPA.S182563 DO - 10.2147/PPA.S182563 ID - Ford2018 ER - TY - STD TI - Nichols R, Doty E, Sacco S, Ruff D, Pearlman E, Aurora SK (2018) Analysis of initial nonresponders to galcanezumab in patients with episodic or chronic migraine: results from the EVOLVE-1, EVOLVE-2, and REGAIN randomized, double-blind, placebo-controlled studies. Headache. https://doi.org/10.1111/head.13443 ID - ref49 ER - TY - JOUR AU - Reuter, U. AU - Goadsby, P. J. AU - Lanteri-Minet, M. AU - Wen, S. AU - Hours-Zesiger, P. AU - Ferrari, M. D. AU - Klatt, J. PY - 2018 DA - 2018// TI - Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study JO - Lancet VL - 392 UR - https://doi.org/10.1016/S0140-6736(18)32534-0 DO - 10.1016/S0140-6736(18)32534-0 ID - Reuter2018 ER - TY - JOUR AU - Blumenfeld, A. M. AU - Bloudek, L. M. AU - Becker, W. J. AU - Buse, D. C. AU - Varon, S. F. AU - Maglinte, G. A. AU - Wilcox, T. K. AU - Kawata, A. K. AU - Lipton, R. B. PY - 2013 DA - 2013// TI - Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II) JO - Headache VL - 53 UR - https://doi.org/10.1111/head.12055 DO - 10.1111/head.12055 ID - Blumenfeld2013 ER - TY - JOUR AU - Rapoport, A. AU - Mauskop, A. AU - Diener, H. C. AU - Schwalen, S. AU - Pfeil, J. PY - 2006 DA - 2006// TI - Long-term migraine prevention with topiramate: open label extension of pivotal trials JO - Headache VL - 46 UR - https://doi.org/10.1111/j.1526-4610.2006.00506.x DO - 10.1111/j.1526-4610.2006.00506.x ID - Rapoport2006 ER - TY - JOUR AU - Pijpers, J. A. AU - Louter, M. A. AU - Bruin, M. E. AU - Zwet, E. W. AU - Zitman, F. G. AU - Ferrari, M. D. AU - Terwindt, G. M. PY - 2016 DA - 2016// TI - Detoxification in medication-overuse headache, a retrospective controlled follow-up study: does care by a headache nurse lead to cure? JO - Cephalalgia VL - 36 UR - https://doi.org/10.1177/0333102415583146 DO - 10.1177/0333102415583146 ID - Pijpers2016 ER - TY - JOUR AU - Russell, F. A. AU - King, R. AU - Smillie, S. J. AU - Kodji, X. AU - Brain, S. D. PY - 2014 DA - 2014// TI - Calcitonin gene-related peptide: physiology and pathophysiology JO - Physiol Rev VL - 94 UR - https://doi.org/10.1152/physrev.00034.2013 DO - 10.1152/physrev.00034.2013 ID - Russell2014 ER - TY - STD TI - Deen M, Hougaard A, Hansen HD, Svarer C, Eiberg H, Lehel S, Knudsen GM, Ashina M (2018) Migraine is associated with high brain 5-HT levels as indexed by 5-HT4 receptor binding. Cephalalgia. https://doi.org/10.1177/0333102418793642 ID - ref55 ER - TY - JOUR AU - Chaitman, B. R. AU - Ho, A. P. AU - Behm, M. O. AU - Rowe, J. F. AU - Palcza, J. S. AU - Laethem, T. AU - Heirman, I. AU - Panebianco, D. L. AU - Kobalava, Z. AU - Martsevich, S. Y. AU - Free, A. L. AU - Bittar, N. AU - Chrysant, S. G. AU - Ho, T. W. AU - Chodakewitz, J. A. AU - Murphy, M. G. AU - Blanchard, R. L. PY - 2012 DA - 2012// TI - A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina JO - Clin Pharmacol Ther VL - 91 UR - https://doi.org/10.1038/clpt.2011.246 DO - 10.1038/clpt.2011.246 ID - Chaitman2012 ER - TY - JOUR AU - Depre, C. AU - Antalik, L. AU - Starling, A. AU - Koren, M. AU - Eisele, O. AU - Lenz, R. A. AU - Mikol, D. D. PY - 2018 DA - 2018// TI - A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina JO - Headache VL - 58 UR - https://doi.org/10.1111/head.13316 DO - 10.1111/head.13316 ID - Depre2018 ER -